-
Cost-Consequence and Clinical Impact of NGS Testing in Advanced Lung Adenocarcinoma: Real-World Evidence From a Portuguese Public Hospital
Sep 9, 2025, 16:22 PM -
Estimating the Mean Time in Treatment-Free Remission for Patients in Early Line CML
Sep 9, 2025, 16:22 PM -
Impact of the Severity of Disease-Related Malnutrition on Healthcare Resource Utilization in Pediatric Patients 1 Year and Older
Sep 9, 2025, 16:22 PM -
Retrospective Analysis of Hungarian HTA Submissions Under the Former National Health Economics Guideline
Sep 9, 2025, 16:22 PM -
Importance of Decisional Context in the Health Technology Assessment (HTA) of Advanced Therapy Medicinal Products (ATMPs)
Sep 9, 2025, 16:22 PM -
Health Economic Assessment of Cefepime-Enmetazobactam for Treating Complicated Urinary Tract Infections: A German Payer Perspective
Sep 9, 2025, 16:22 PM -
Budget Impact Analysis of Direct Oral Anticoagulants vs. Vitamin K Antagonists in Algeria: A Public Payer Perspective
Sep 9, 2025, 16:22 PM -
Generalizability of Patient Preference Study Results: A Weight and Test Approach
Sep 9, 2025, 16:22 PM -
Artificial Intelligence in Pharmaceutical Payer Decision Making—Assessing Current Use, Strategic Intent, and Infrastructure Readiness
Sep 9, 2025, 16:22 PM -
When Less Is More? Learnings From a Recent NICE Submission Utilizing a Novel Predictive Individual-Level Surrogacy Approach to Predict Overall Survival (OS) in the Absence of Trial-Level Evidence
Sep 9, 2025, 16:22 PM -
The SISAQOL-IMI Recommendations on Standardizing the Use of Thresholds for Interpretation of Patient-Reported Outcome Results in Cancer Clinical Trials
Sep 9, 2025, 16:22 PM -
Embedding Patient Experience Data (PED) in EU Joint Clinical Assessments: Strategic Imperatives and Evidence Practices
Sep 9, 2025, 16:22 PM -
Acceptance of Clinical Studies Conducted in Nonus Settings by the FDA Based on the Analysis of Selected Novel Drug Approvals
Sep 9, 2025, 16:22 PM -
Healthcare Resource Utilization Associated With Acute Pancreatitis in Patients With Familial Chylomicronemia Syndrome Treated With Olezarsen: A Post Hoc Analysis of Balance Study Data
Sep 9, 2025, 16:22 PM -
Cost-Utility Analysis of Standard-Dose vs. High-Dose Influenza Vaccination in Adults Aged ≥65 Years in Italy
Sep 9, 2025, 16:22 PM -
Economic Evaluation of the Adoption of Peritoneal Dialysis for Newly Diagnosed Hemodialysis Ineligible Pediatric End-Stage Kidney Disease Patients in Egypt
Sep 9, 2025, 16:22 PM -
Melatonin Use Among Children and Adolescents: A Finnish Nationwide Drug Utilization Study
Sep 9, 2025, 16:22 PM -
Mapping to EQ-5D Utility in Knee Osteoarthritis: A Comparative Evaluation of WOMAC and SF-36 Algorithms in the STEP 9 Trial
Sep 9, 2025, 16:22 PM -
Review of Rare Disease Policy Developments in Europe and Türkiye 2020-2025 in the Context of Innovative Orphan Drugs
Sep 9, 2025, 16:22 PM -
Are We Measuring What Matters in Postpartum Depression Trials?
Sep 9, 2025, 16:22 PM
